Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 5/20 | 0.53 |
| ▸ | PI4K2B | Q8TCG2 | 5/20 | 0.53 |
| ▸ | PI4K2A | Q9BTU6 | 5/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 5/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.48 |
| ▸ | AHCY | P23526 | 6/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | ADA | P00813 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5080093 | 0.74 | PI4KA (0.63) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL20052484 | 0.73 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL11476962 | 0.72 | PI4KA (0.75) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL5083002 | 0.71 | PI4KA (0.53) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL5021593 | 0.71 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL17641488 | 0.71 | ADORA2A (0.56) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL20253540 | 0.69 | PI4KA (0.74) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL22666249 | 0.69 | PI4KA (0.74) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL30969137 | 0.69 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL20049726 | 0.69 | PI4KA (0.75) | PI4KAPI4K2BPI4K2API4KBADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170088577-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088577-A1 | MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS | PNP, UGT1A3, UGT2B7 | PI4KA 879/4885PI4K2B 759/4885PI4K2A 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.